A Phase 3 interventional study of Ixekizumab in Psoriasis, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 20th largest by enrollment, is one of 3 that started in 2015, is one of 11 in phase 3, and was the 7th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 34th largest by enrollment, is one of 3 that started in 2015, is one of 15 in phase 3, and was the 11th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
Drug: Ixekizumab
160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.
Drug: Ixekizumab
Administered SC
Also known as: LY2439821
Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score
The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 Numeric Rating Score (NRS) the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.
Time frame: Baseline through Week 12
Mean Change From Baseline on Itch Numeric Rating Scale (NRS) Score
The Itch NRS is a patient-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Least Square Means (LS means) are from analysis of mixed-effects model for repeated measures (MMRM) and model includes treatment group, baseline value and timepoint.
Time frame: Baseline, Week 12
Mean Change From Baseline on the Dermatology Life Quality Index (DLQI)
The DLQI is a simple, patient-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). LS means are from analysis of MMRM and model includes treatment group, baseline value and timepoint.
Time frame: Baseline, Week 12
Mean Change From Baseline in Percent Body Surface Area (%BSA)
The BSA is the percentage involvement of psoriasis on each participant's body surface on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including the palm, fingers, and thumb). The total BSA affected was the summation of individual regions affected. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction
Time frame: Baseline, Week 12
Mean Change From Baseline on the Psoriasis Area and Severity Index (PASI)
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in PASI scores compared to baseline. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction.
Time frame: Baseline, Week 12
Time to at Least a 2 Point Improvement on the PatGA Score
The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 NRS the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.
Time frame: Baseline though Week 12
Induction Dosing Period (Weeks 0 up to 12), Maintenance Dosing Period (Weeks 12 up to 48), Minimum Post Treatment Follow-Up Period up to 12 weeks after last visit.
| Milestone | Ixekizumab Q2W | Ixekizumab Q4W |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Ixekizumab Q2W | Ixekizumab Q4W |
|---|---|---|
| Started | 0 | 12 |
| Completed | 0 | 12 |
| Not completed | 0 | 0 |
| Milestone | Ixekizumab Q2W | Ixekizumab Q4W |
|---|---|---|
| Started | 0 | 12 |
| Completed | 0 | 12 |
| Not completed | 0 | 0 |
The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 Numeric Rating Score (NRS) the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.
| Days | Ixekizumab Q2W | Ixekizumab Q4W |
|---|---|---|
| Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score | 5.0 (2.0 to 5.0) | 6.0 (4.0 to 7.0) |
The Itch NRS is a patient-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Least Square Means (LS means) are from analysis of mixed-effects model for repeated measures (MMRM) and model includes treatment group, baseline value and timepoint.
| units on a scale | Ixekizumab Q2W | Ixekizumab Q4W |
|---|---|---|
| Mean Change From Baseline on Itch Numeric Rating Scale (NRS) Score | -6.2 ± 0.53 | -6.6 ± 0.55 |
The DLQI is a simple, patient-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). LS means are from analysis of MMRM and model includes treatment group, baseline value and timepoint.
| units on a scale | Ixekizumab Q2W | Ixekizumab Q4W |
|---|---|---|
| Mean Change From Baseline on the Dermatology Life Quality Index (DLQI) | -13.4 ± 1.56 | -14.3 ± 1.59 |
The BSA is the percentage involvement of psoriasis on each participant's body surface on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including the palm, fingers, and thumb). The total BSA affected was the summation of individual regions affected. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction
| percentage of body surface area | Ixekizumab Q2W | Ixekizumab Q4W |
|---|---|---|
| Mean Change From Baseline in Percent Body Surface Area (%BSA) | -26.1 ± 1.39 | -28.0 ± 1.39 |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in PASI scores compared to baseline. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction.
| units on a scale | Ixekizumab Q2W | Ixekizumab Q4W |
|---|---|---|
| Mean Change From Baseline on the Psoriasis Area and Severity Index (PASI) | -22.00 ± 0.456 | -22.72 ± 0.456 |
The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 NRS the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.
| Days | Ixekizumab Q2W | Ixekizumab Q4W |
|---|---|---|
| Time to at Least a 2 Point Improvement on the PatGA Score | 10.0 (6.0 to 12.0) | 13.5 (5.0 to 22.0) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixekizumab Q2W Induction Dosing Period | — | 0/6 (0%) | 5/6 (83.3%) |
| Ixekizumab Q4W Induction Dosing Period | — | 0/6 (0%) | 5/6 (83.3%) |
| Ixekizumab 80 mg Q4W Maintenance | — | 0/12 (0%) | 9/12 (75%) |
| Ixekizumab 80 mg Q4W Post-treatment | — | 0/12 (0%) | 1/12 (8.3%) |
| Event | Ixekizumab Q2W Induction Dosing Period | Ixekizumab Q4W Induction Dosing Period | Ixekizumab 80 mg Q4W Maintenance | Ixekizumab 80 mg Q4W Post-treatment |
|---|---|---|---|---|
| Injection site urticariaGeneral disorders | 0/6 | 2/6 | 0/12 | 0/12 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 1/6 | 4/12 | 0/12 |
| Biopsy prostateInvestigations | 0/5 | 1/3 | 0/8 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/6 | 0/6 | 0/12 | 0/12 |
| Injection site erythemaGeneral disorders | 1/6 | 1/6 | 1/12 | 0/12 |
| HordeolumInfections and infestations | 0/6 | 1/6 | 0/12 | 0/12 |
| InfluenzaInfections and infestations | 0/6 | 0/6 | 2/12 | 0/12 |
| Localised infectionInfections and infestations | 1/6 | 0/6 | 0/12 | 0/12 |
| Biopsy breastInvestigations | 0/6 | 0/6 | 2/12 | 0/12 |
| AcneSkin and subcutaneous tissue disorders | 1/6 | 0/6 | 0/12 | 0/12 |
| Age, Continuous(years) | Ixekizumab Q2W | Ixekizumab Q4W | Total |
|---|---|---|---|
| Mean | 41.8 ± 12.54 | 55.2 ± 7.39 | 48.5 ± 12.03 |
| Sex: Female, Male(Participants) | Ixekizumab Q2W | Ixekizumab Q4W | Total |
|---|---|---|---|
| Female | 1 | 3 | 4 |
| Male | 5 | 3 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Ixekizumab Q2W | Ixekizumab Q4W | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 5 | 4 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ixekizumab Q2W | Ixekizumab Q4W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 4 | 5 | 9 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Ixekizumab Q2W | Ixekizumab Q4W | Total |
|---|---|---|---|
| United States | 6 | 6 | 12 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Apr 2015, a primary completion of Sep 2015 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab